Versant backs new approach to gamma delta T cells, co-leads Lava's $18.9M round
With immuno-oncology dominating pipelines these days, the field of gamma delta T cells — once a tiny area of study — is gaining some steam. The newest …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
